In patients undergoing percutaneous coronary intervention (PCI), continuing the administration of bivalirudin for 2-4 hours after PCI reduced the risk of a composite of all-cause mortality or major bleeding compared to post-procedural heparin monotherapy, according to new randomized trial results.